A playbook with 43 detailed analyses for a biotechnology company
Each analysis includes:
- Goal of the analysis
- Data required
- Detailed step-by-step instruction on how to conduct the analysis
- Format of the output of analysis
- How to interpret results
- Steps a company can take to improve on the measure
In this guide you'll learn the following 43 analyses across six categories:
Table of Contents
A. Research & Development
- Pipeline Analysis
- Clinical Trial Progress and Outcomes
- Preclinical Data Quality and Translational Potential
- Gene Therapy or Genetic Engineering Platform Evaluation
- Cell Line Development and Optimization Analysis
- Regenerative Medicine and Stem Cell Platform Assessment
- Biomarker Strategy and Companion Diagnostic Development
- Immunogenicity Risk and Management for Biologics
- Toxicology and Safety Pharmacology Study Outcomes
- Personalized Medicine Strategy and Customization Potential
- Viral Vector Development and Optimization for Gene Delivery
- Advanced Drug Delivery Systems
- Monoclonal Antibody (mAb) Engineering and Optimization
- CAR-T Cell Therapy Efficacy and Expansion Potential
- Bioconjugation and Targeted Therapy Efficacy
- Cellular Microenvironment Manipulation for Therapeutic Benefit
- Protein Folding and Stability in Biopharmaceuticals
- Gene-Environment Interaction Studies for Precision Medicine
B. Operations
- Regulatory Pathways
- Manufacturing and Scalability Assessment
- Orphan Drug Designation and Exclusivity Opportunities
- Manufacturing Process Intellectual Property
- Supply Chain Security and Raw Material Sourcing
- Clinical Trial Patient Recruitment and Retention Strategies
- Pharmacovigilance and Post-Market Surveillance Plans
- Biomanufacturing Facility Compliance and GMP Standards
- Clinical Data Integration with Real-World Evidence (RWE)
- Adaptive Trial Design and Utilization in Drug Development
C. Marketing
- Competitive Landscape and Differentiation of Technology
- Market Size and Commercial Viability for Lead Products
- Therapeutic Area Expertise and Alignment with Unmet Needs
- Biosimilar Product Development and Market Strategy
- Biologic vs. Small Molecule Product Differentiation
- Market Access and Value Demonstration Strategy
D. Technology
E. Finance
F. Organization